Results 121 to 130 of about 607,655 (152)

Fumarate and Its Esters: Physiology, Pathology, Molecular Mechanisms, Diseases, and Therapy

MedComm, Volume 7, Issue 10, October 2026.
Fumarate is an endogenous immunometabolite that regulates metabolism, redox homeostasis, and inflammation. Although fumaric acid esters (FAEs) share several molecular targets with fumarate, their distinct physicochemical properties confer unique biological activities and therapeutic applications.
Peng Zhu, Mengling You, Yi Zeng, Jinglin Zhang, Si Chen, Rong Rong, Xiaobo Xia   +6 more
wiley   +1 more source

Drug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Tocilizumab is an interleukin‐6 (IL‐6) receptor antagonist indicated for various rheumatologic conditions. While hepatotoxicity is a recognized adverse effect, it predominantly manifests as hepatocellular injury. We report a rare case of drug‐induced liver injury (DILI) presenting with a cholestatic pattern and cholangitis features in a 75 ...
Louis‐Edmond Barbaro, Nouha Ben Othman, Delphine Viard, Fanny Rocher, Elliot Ewig, Raja Mroue, Claire Amigues, Alexandre O. Gérard   +7 more
wiley   +1 more source

The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept

, 2011
To investigate the effectiveness of etanercept on axial manifestations of a group of patients with established psoriatic arthritis (PsA)
Lubrano, Ennio, Spadaro, Antonio, Helliwell, Philip, Olivieri, Ignazio, Marchesoni, Antonio, Scarpa, Raffaele, Ferrara, Nicola, D'Angelo, Salvatore, SALVARANI, CARLO, Cauli, Alberto, Mathieu, Alessandro, Lubrano Di Scorpaniello, Ennio   +11 more
core  

Valid Data‐Driven Subgroup Selection With Uniform Guarantees in Clinical Trials

Statistics in Medicine, Volume 45, Issue 23-24, October 2026.
ABSTRACT Subgroup selection in clinical trials is essential for identifying patient groups that react differently to a treatment, thereby enabling personalized medicine. In particular, subgroup selection can identify patient groups that respond particularly well to a treatment or that encounter adverse events more often.
Manuel M. Müller, Björn Bornkamp, Frank Bretz, Timothy I. Cannings, Wei Liu, Henry W. J. Reeve, Richard J. Samworth, Nikolaos Sfikas, Fang Wan, Konstantinos Sechidis   +9 more
wiley   +1 more source

PO:03:036 | Psoriatic arthritis: does pre-existing treatment with cs/bDMARDs for psoriasis influence the characteristics and outcomes of joint disease?

Reumatismo
Background. Several studies have shown that treatment of psoriasis with cs/bDMARDs reduces the risk of developing psoriatic arthritis. The aim of this study is to investigate and compare the characteristics of patients who developed psoriatic arthritis ...
Società Italiana di Reumatologia
doaj  

Exploratory MRI and Clinical Marker Analysis of Pustulotic Arthro‐Osteitis Disease Activity From a Phase 3 Brodalumab Trial

The Journal of Dermatology, Volume 53, Issue 10, Page 1448-1456, October 2026.
ABSTRACT Pustulotic arthro‐osteitis (PAO) is a clinically important osteoarticular comorbidity affecting approximately 9%–28% of patients with palmoplantar pustulosis (PPP), yet early recognition and standardized activity assessment remain challenging, particularly in routine dermatology practice.
Taiki Nozaki, Manabu Arai, Junko Ochi, Mona Uchida‐Yamada, Masahiro Hashimoto, Mitsuhiro Akiyama, Yuko Kaneko, Yasumasa Kanai, Masahiro Jinzaki   +8 more
wiley   +1 more source

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, Volume 78, Issue 10, Page 1317-1323, October 2026.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9543-9551, October 2026.
ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu, Chengsheng Ju, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Scottish Diabetes Research Network Epidemiology Group, Peter Hanlon, Robert Lindsay, David McAllister, John Petrie, Naveed Sattar, Brian Kennon, Sam Philip, Scott Cunningham, Huan Wang, William Berthon, Helen Colhoun, Paul McKeigue, Sarah Wild, Ewan R. Pearson, Li Wei, Ruth Andrew   +20 more
wiley   +1 more source

PDE4 Inhibition in Dermatologic Disease: Impacts Beyond Inflammation

International Journal of Dermatology, Volume 65, Issue 10, Page 2038-2048, October 2026.
This graphical abstract demonstrates the comprehensive mechanism of PDE4 inhibition in skin physiology. By increasing intracellular cAMP and activating PKA, PDE4 inhibitors exert pleiotropic effects, including immune modulation, pigmentation regulation, barrier enhancement, sensory neuron modulation, and improved wound healing with reduced fibrosis ...
Keana Khodadad, Nicole E. Chin, Raj Chovatiya   +2 more
wiley   +1 more source

Therapies for axial disease in psoriatic arthritis. A systematic review

, 2006
Prevalence rates for axial involvement in psoriatic arthritis (PsA) vary from 40% to 74% depending upon criteria for diagnosis. In the absence of trial evidence to assess axial involvement in PsA.
Nash, Peter
core